Tom Hu, DO
Interventional Cardiology · Tulsa, OKNPI 1518316314
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (54.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Abbott at 41.7% of the total. Reporting peaked in 2023 at $37,353 and has fallen 87.1% since, to $4,832 in 2025. Among interventional cardiology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $168.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$24K
- Boston Scientific$18K
- Medtronic$4K
- Edwards Lifesciences$3K
- W. L. Gore & Associates, Inc.$1K
- Abiomed$1K
- plus $5K from 25 others
What the payments were for
- Grants$31,00055%
- Travel & lodging$9,31716%
- Food & beverage$15,63728%
- Education$6021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 87 | $23,579 |
| Boston Scientific | 36 | $18,109 |
| Medtronic(2 entities) | 34 | $3,577 |
| Edwards Lifesciences | 33 | $3,044 |
| W. L. Gore & Associates, Inc. | 11 | $1,441 |
| Abiomed | 16 | $1,438 |
| Philips North America LLC | 8 | $979 |
| Inari Medical, Inc. | 10 | $910 |
| Novartis | 41 | $752 |
| Penumbra, Inc. | 3 | $414 |
| Angiodynamics, Inc. | 4 | $267 |
| Johnson & Johnson | 6 | $209 |
| Astellas Pharma US Inc | 2 | $200 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $189 |
| Atricure, Inc. | 2 | $172 |
| Chiesi USA, Inc. | 4 | $160 |
| Cardiva Medical, Inc. | 2 | $144 |
| Shockwave Medical, Inc | 1 | $144 |
| Amgen | 6 | $118 |
| Terumo Medical Corporation | 1 | $110 |
| Stryker | 3 | $107 |
| Baxter Healthcare | 2 | $87 |
| Asahi Intecc USA, Inc. | 2 | $73 |
| AstraZeneca | 4 | $67 |
| Biosense Webster, Inc. | 1 | $62 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Actelion Pharmaceuticals US, Inc. | 1 | $41 |
| Pfizer | 2 | $37 |
| Bayer | 2 | $31 |
| Boehringer Ingelheim | 2 | $27 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$2,301
- MitraClip$1,231
- GENERAL - STENTS$1,000
- Impella$985
- Allure CRT Pacemaker$907
- TRICLIP$893
- US Und$870
- Edwards SAPIEN 3 Transcatheter Heart Valve$814
- FLOWTRIEVER CATHETER, S$759
- CT THROMBECTOMY SYSTEM KIT$759
- Assurity Pacemaker$715
- GORE CARDIOFORM ASD Occluder$669
- GORE CARDIOFORM Septal Occluder$613
- Quadra Assura CRT Defibrillator$551
- SAPIEN 3 Ultra RESILIA$497
- NAVITOR$496
- Indigo System$414
- WATCHMAN FLX$382
- OPTIS$315
- GENERAL - THERAPIES$301
How this compares
$56,556 in reported general payments places this provider in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $20,603 |
| Atorvastatin Calcium | 35 | $1,031 |
| Torsemide | 13 | $183 |
| Rosuvastatin Calcium | 12 | $179 |
| Carvedilol | 18 | $163 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $154 |
| Nitroglycerin | 16 | $151 |
| Amlodipine Besylate | 22 | $145 |
| Metoprolol Succinate | 12 | $141 |
| Metoprolol Tartrate | 18 | $129 |
| Furosemide | 21 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $37 | $20,60314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
- Arash KarnamaTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.